Compare THO & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THO | GKOS |
|---|---|---|
| Founded | 1980 | 1998 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.3B |
| IPO Year | 1994 | 2015 |
| Metric | THO | GKOS |
|---|---|---|
| Price | $115.67 | $121.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $113.75 | ★ $133.07 |
| AVG Volume (30 Days) | 402.8K | ★ 770.3K |
| Earning Date | 03-04-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ 0.36 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $9,579,490,000.00 | $383,481,000.00 |
| Revenue This Year | $1.72 | $23.29 |
| Revenue Next Year | $5.14 | $27.74 |
| P/E Ratio | $21.88 | ★ N/A |
| Revenue Growth | N/A | ★ 21.85 |
| 52 Week Low | $63.16 | $73.16 |
| 52 Week High | $122.83 | $142.50 |
| Indicator | THO | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 54.38 |
| Support Level | $112.14 | $103.55 |
| Resistance Level | $117.14 | $121.70 |
| Average True Range (ATR) | 3.90 | 5.58 |
| MACD | -0.78 | -0.11 |
| Stochastic Oscillator | 25.14 | 72.81 |
Based in Elkhart, Indiana, Thor Industries manufactures Class A, Class B, and Class C motor homes along with travel trailers and fifth-wheel towables across about 35 brands. Through the acquisition of Erwin Hymer in 2019, the company expanded its geographic footprint and now produces various motorized and towable recreational vehicles for Europe, including motor caravans, camper vans, urban vehicles, caravans, and other RV-related products and services. The company has also begun generating revenue through aftermarket component parts via the acquisition of Airxcel in 2021; however, this is still a nascent part of the business as it accounts for less than 10% of fiscal 2025 total sales. In fiscal 2025, the company wholesaled 181,388 units and generated $9.6 billion in revenue.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.